| Indira Misra Higgins, DO PLLC | |
|
31815 Southfield Rd, Suite 18, Beverly Hills, MI 48025-5471 | |
| (248) 723-5802 | |
| (248) 723-5838 |
| Full Name | Indira Misra Higgins |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 29 Years |
| Location | 31815 Southfield Rd, Beverly Hills, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366426454 | NPI | - | NPPES |
| MI1077 | Other | MI | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 5101012883 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Entity Name | Indira C Misra Higgins Do Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700044864 PECOS PAC ID: 3072673235 Enrollment ID: O20081118000072 |
News Archive
Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.
Within minutes after birth, every child in the U.S. undergoes a battery of tests designed to diagnose a host of conditions, including sickle cell disease. Thousands of children born in the developing world, however, aren't so lucky, meaning many suffer and die from the disease each year.
Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
Just because you can't see something doesn't mean it's not there. Brain tumors are an extremely serious example of this and are not only difficult to treat-both adult and pediatric patients have a five-year survival rate of only 30 percent-but also have even been difficult to image, which could provide important information for deciding next steps in the treatment process.
› Verified 5 days ago
| Entity Name | Beaumont Medical Group- Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578072906 PECOS PAC ID: 7214299866 Enrollment ID: O20180320002549 |
News Archive
Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.
Within minutes after birth, every child in the U.S. undergoes a battery of tests designed to diagnose a host of conditions, including sickle cell disease. Thousands of children born in the developing world, however, aren't so lucky, meaning many suffer and die from the disease each year.
Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
Just because you can't see something doesn't mean it's not there. Brain tumors are an extremely serious example of this and are not only difficult to treat-both adult and pediatric patients have a five-year survival rate of only 30 percent-but also have even been difficult to image, which could provide important information for deciding next steps in the treatment process.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Indira Misra Higgins, DO PLLC 31815 Southfield Rd, Suite 18, Beverly Hills, MI 48025-5471 Ph: (248) 723-5802 | Indira Misra Higgins, DO PLLC 31815 Southfield Rd, Suite 18, Beverly Hills, MI 48025-5471 Ph: (248) 723-5802 |
News Archive
Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.
Within minutes after birth, every child in the U.S. undergoes a battery of tests designed to diagnose a host of conditions, including sickle cell disease. Thousands of children born in the developing world, however, aren't so lucky, meaning many suffer and die from the disease each year.
Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
Just because you can't see something doesn't mean it's not there. Brain tumors are an extremely serious example of this and are not only difficult to treat-both adult and pediatric patients have a five-year survival rate of only 30 percent-but also have even been difficult to image, which could provide important information for deciding next steps in the treatment process.
› Verified 5 days ago